Gary Nachman
Stock Analyst at Raymond James
(3.55)
# 805
Out of 4,847 analysts
97
Total ratings
59.09%
Success rate
2.44%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Outperform | $218 → $220 | $186.99 | +17.65% | 14 | Feb 3, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $21.69 | +29.09% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $306.09 | -2.64% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $28.93 | +27.89% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.90 | +412.82% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $26.26 | +40.93% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $11.45 | +65.94% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $288.47 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $29.77 | +0.77% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $2.81 | +149.11% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.58 | +419.84% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $108.29 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $7.42 | -46.06% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $4.64 | +546.55% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $34.13 | +96.31% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.14 | +1,395.33% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $8.69 | +61.10% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $6.62 | +504.23% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $17.26 | -42.06% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $20.15 | +48.88% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $2.95 | +25,323.73% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $4.48 | +78.57% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $25.38 | -17.26% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $3.84 | +264.58% | 2 | Jun 14, 2018 |
AbbVie
Feb 3, 2025
Reiterates: Outperform
Price Target: $218 → $220
Current: $186.99
Upside: +17.65%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $21.69
Upside: +29.09%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $306.09
Upside: -2.64%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $28.93
Upside: +27.89%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.90
Upside: +412.82%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $26.26
Upside: +40.93%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $11.45
Upside: +65.94%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $288.47
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $29.77
Upside: +0.77%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $2.81
Upside: +149.11%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.58
Upside: +419.84%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $108.29
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $7.42
Upside: -46.06%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $4.64
Upside: +546.55%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $34.13
Upside: +96.31%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.14
Upside: +1,395.33%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $8.69
Upside: +61.10%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $6.62
Upside: +504.23%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $17.26
Upside: -42.06%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $20.15
Upside: +48.88%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $2.95
Upside: +25,323.73%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $4.48
Upside: +78.57%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $25.38
Upside: -17.26%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $3.84
Upside: +264.58%